Research Information System
XXXI MEETING OF BALKAN CLINICAL LABORATORY FEDERATION 35th NATIONAL BIOCHEMISTRY CONGRESS, Antalya, Turkey, 28 October - 01 November 2024, vol.49, no.2024, pp.128, (Summary Text)
INHIBITION OF ESTROGEN-DEPENDENT PROLIFERATION IN BREAST AND OVARIAN CANCER CELLS BY SPARSTOLONIN B Yağmur Dilber1 , Hanife Tuğçe Çeker1 , Aleyna Öztüzün1 , Bürke Çırçırlı2 , Mutay Aslan1 1 Akdeniz University, Faculty of Medicine, Department of Medical Biochemistry, Antalya, Türkiye 2 Akdeniz University, Faculty of Medicine, Department of Medical Biotechnology, Antalya, Türkiye Objectives: Estrogen hormone has an important role in breast and ovarian cancer by increasing cell proliferation. Sparstolonin B is a polyphenol which has menstrual cycle regulatory effects, anti-inflammatory and immunomodulatory properties. The time and dose dependent effect of Sparstolonin B on cell viability and proliferation was investigated in breast, ovarian cancer and healthy human fibroblasts with and without the presence of estradiol hemihydrate. Methods: Human breast cancer (MCF-7), human ovarian cancer (OVCAR-3) and human fibroblast (BJ) cell lines were treated with estrogen (1-100 nM) and/or sparstolonin B (3,125-50 µM) between 16-48 hours. Cell viability was assessed by MTT analysis, while cell proliferation was demonstrated by Proliferating Cell Nuclear Antigen (PCNA) measurement via ELISA and immunofluorescence microscopy. Apoptotic cells were demonstrated by the TUNEL method. Results: Estrogen (10 nM, 48 hours) significantly increased proliferation in MCF-7 breast cancer and Ovcar-3 ovarian cancer cells (up to 270%),but did not have a significant effect on BJ fibroblasts. Sparstolonin B (25 µM, 24 hours) significantly reduced cell viability in MCF-7 and Ovcar-3 (down to 25-27%) without harming healthy fibroblasts. It also inhibited estrogen-induced proliferation and significantly reduced apoptosis in these cancer cells. Conclusions: In this study, antiproliferative activity of SsnB application was demonstrated in breast and ovarian cancer cells subjected to estrogen-dependent proliferation. The fact that the applied SsnB concentration did not have a toxic effect on healthy fibroblast cells supports the development of this agent as a potential therapeutic in estrogen-dependent cancer types. Keywords: Sparstolonin B, Breast Cancer, Ovarian Cancer, Estrojen proliferation